{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:22Z","timestamp":1792806142619,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04376-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:20:42Z","timestamp":1779456042000},"page":"5434-5439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors influencing the use of hypofractionated radiotherapy in prostate cancer: a nationwide survey of radiation oncologists in Turkiye (TROD 09\u2014008)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-1259","authenticated-orcid":false,"given":"Zuleyha","family":"Akgun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1221-9192","authenticated-orcid":false,"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eefik","family":"\u0130\u011fdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"2","key":"4376_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018;8:354\u2013360.","journal-title":"Eur Urol"},{"key":"4376_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrurol.2017.119","volume":"14","author":"NG Zaorsky","year":"2017","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024 Aug;86(2):148-163.","journal-title":"Nat Rev Urol"},{"key":"4376_CR3","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al.\u00a0Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047-1060.","journal-title":"J Clin Oncol"},{"key":"4376_CR4","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al.\u00a0Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017 Jun 10;35(17):1884-1890.","journal-title":"J Clin Oncol"},{"key":"4376_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 Jul 10;34(20):2325-32.","journal-title":"Lancet"},{"key":"4376_CR6","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385\u2013395.","journal-title":"Lancet Oncol"},{"key":"4376_CR7","first-page":"52","volume":"24","author":"L Incrocci","year":"2023","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity outcomes. Lancet Oncol. 2019;20:1531\u20131543.","journal-title":"Lancet Oncol"},{"key":"4376_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for localized prostate cancer (HYPRO): 10-year results of a randomized, non-inferiority, phase 3 trial. Lancet Oncol. 2023;24:52\u201364.","journal-title":"JAMA Netw Open"},{"key":"4376_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2:e188006.","journal-title":"Pract Radiat Oncol"},{"key":"4376_CR10","first-page":"1449","volume":"375","author":"A Trofimov","year":"2016","unstructured":"Alongi F, Fiorentino A, De Bari B. SBRT and extreme hypofractionation: A new era in prostate cancer treatments? Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):411-6.","journal-title":"N Engl J Med"},{"key":"4376_CR11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2018.10.020","volume":"132","author":"F Alongi","year":"2019","unstructured":"Dearnaley D, Syndikus I, Gulliford S, Hall E. Hypofractionation for Prostate Cancer: Time to Change. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):3-5.","journal-title":"Radiother Oncol"},{"key":"4376_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"\u00a0Viani GA, Gouveia AG, Leite ETT, Moraes FY. Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: A cohort study with meta-analysis. Radiother Oncol. 2022 Jun;171:7-13.","journal-title":"J Clin Oncol"},{"key":"4376_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018 Feb 10;36(5):446-453.","journal-title":"Pract Radiat Oncol"},{"key":"4376_CR14","first-page":"242","volume":"27","author":"TJ Royce","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017 Jan-Feb;7(1):4-12.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"4376_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1186\/s12885-019-6285-x","volume":"19","author":"W Guo","year":"2019","unstructured":"Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, Patrocinio H, et al. Practical considerations for prostate hypofractionation in the developing world. Nat Rev Urol. 2021 Nov;18(11):669-685.","journal-title":"BMC Cancer"},{"key":"4376_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","volume":"15","author":"CT Cunningham","year":"2015","unstructured":"Guo W, Sun YC, Bi JQ, He XY, Xiao L. Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials. BMC Cancer. 2019 Nov 8;19(1):1063.","journal-title":"BMC Med Res Methodol"},{"key":"4376_CR17","doi-asserted-by":"publisher","unstructured":"Tess C, Hude C, Brenda Q, Tom H, Cynthia N, Elijah B, et al. Exploring physicianspecialist response rates to web-based surveys. BMC Medical Research Methodology. 2015;15(1). https:\/\/doi.org\/10.1186\/s12874-015-0016-z.","DOI":"10.1186\/s12874-015-0016-z"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04376-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:20Z","timestamp":1792803740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4376"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04376-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial or non-financial interests that could have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the non-interventional nature of the study and the absence of patient-level data, formal ethical approval was not required in accordance with institutional policies.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participation was voluntary and anonymous. Completion of the survey was considered implied consent.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}